Uncategorized

The company said the investment will create high-paying jobs and add lab services capacity to its domestic healthcare supply chain.

Although HCA beat the street’s expectations for profit in the first quarter, analysts said reaffirming its guidance is a “prudent” move given possible headwinds from Washington.

William Blair analyst Brandon Vazquez said 2025 could be the first year market leader Intuitive Surgical will face meaningful U.S. competition.

While J&J, Abbott and Boston Scientific have all said the White House’s tariff policies will cost them hundreds of millions of dollars, yearly forecasts have remained in place — or even increased.

An analysis of the timing of adverse event reports has convinced the company that raw material delivered by a vendor was the source of the problem.

Spruce Biosciences is cutting over half of its employees as it looks to secure accelerated approval of a Sanfilippo syndrome therapy it recently acquired from BioMarin.

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due to any cause or persistence of cancer cells by 32% in patients with high-risk non-muscle invasive bladder cancer.

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the air.

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect potentially practice-changing data in head and neck and lung cancer and key updates on hot modalities.